Curocell

Curocell Earnings Yield

The Earnings Yield of Curocell (372320.KQ) as of Nov 3, 2026 is -6.50 %. In the previous year, Earnings Yield was -5.36 % — a change of 21.09% (lower).

Earnings Yield

-6.50 %

YoY

21.09%

Last updated:

Earnings Yield of Curocell is 2025 -6.50 % . Earnings Yield of Curocell was 2024 -5.36 % . It decreases by 21.09% lower compared to the previous year.

The Curocell Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2021
-7.52 KRW
Jan 1, 2022
-5.46 KRW
Jan 1, 2023
-4.15 KRW
Jan 1, 2024
-5.36 KRW
Jan 1, 2025
-6.50 KRW
The Curocell Earnings Yield history
YEAREarnings YieldYoY
-6.50 %+21.09%
-5.36 %+29.30%
-4.15 %-23.94%
-5.46 %-27.42%
-7.52 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curocell Stock analysis

What does Curocell do? Curocell Inc makes money through the development and commercialization of CAR-T therapy technologies for cancer treatment. The company focuses on novel chimeric antigen receptor (CAR)-T therapies targeting specific cancer antigens, improving medicinal effects, reducing side effects, and automating quality analysis. These products are developed for pharmaceutical companies and healthcare providers seeking advanced cancer treatments. The firm's R&D efforts target the biotechnology sector, specifically oncology applications. Curocell Inc's business model centers on creating innovative CAR-T therapies that address unmet medical needs in cancer care. The company's research and development activities are directed at enhancing the efficacy and safety of CAR-T treatments, which are sold to pharmaceutical firms for further development and distribution. The firm's products are positioned within the biotechnology industry, catering to the growing demand for targeted cancer therapies. The company's revenue streams come from the sale of its developed CAR-T technologies to pharmaceutical partners. These partnerships enable the commercialization of Curocell's innovations in the global oncology market. Curocell Inc operates within the biotechnology sector, specifically focusing on the development of next-generation CAR-T therapies for cancer patients. Curocell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curocell stock

Earnings Yield of Curocell is -6.50 % in 2025.

Earnings Yield of Curocell changed from -5.36 % to -6.50 %, representing a 21.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Curocell since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Curocell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Curocell

All Key Metrics — Curocell